Rise and shine, everyone, another busy day is on the way. Summertime may still be with us, but there is work to be done. To cope, yes, we are firing up the coffee kettle and downing a few cups of stimulation — we are still stuck on cinnamon dolce, for those tracking this sort of thing. Meanwhile, here are a few items of interest to help you with your own busy routine. We hope your day is productive and you conquer the world, such as it is. And of course, do keep safe. …

Sanofi (SNY) has drawn another blank in its attempt to repurpose its Kevzara rheumatoid arthritis drug to tackle the extreme immune reaction seen in serious cases of Covid-19, Pharmaphorum says. The drug failed to meet the main goals of a U.S. study testing it in the most critically ill Covid-19 patients. As a result, Sanofi and its partner, Regeneron Pharmaceuticals (REGN), do not anticipate conducting further clinical studies for Kevzara for combating the coronavirus.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy